NCT01748747View on ClinicalTrials.gov

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 14, 2014

Study Completion Date

March 30, 2017

Conditions
Recurrent MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
DRUG

Montanide ISA 51 VG

Given SC

BIOLOGICAL

MART-1 antigen

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

Gag:267-274 peptide vaccine

Given SC

DRUG

resiquimod

Applied topically

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | Biotech Hunter | Biotech Hunter